Fonte: Multiple Sclerosis and Related Disorders. Unidade: ICB
Assuntos: IMUNOLOGIA, ESCLEROSE MÚLTIPLA, DOENÇAS DO SISTEMA NERVOSO CENTRAL, NEUROMIELITE ÓPTICA, DOENÇAS DO NERVO ÓPTICO, VACINAS VIRAIS, COVID-19
ABNT
FRAGOSO, Yara Dadalti et al. New relapse of multiple sclerosis and neuromyelitis optica as a potential adverse event of AstraZeneca AZD1222 vaccination for COVID-19. Multiple Sclerosis and Related Disorders, v. 57, p. 1-5, 2022Tradução . . Disponível em: https://doi.org/10.1016/j.msard.2021.103321. Acesso em: 31 out. 2024.APA
Fragoso, Y. D., Gomes, S., Gonçalves, M. V. M., Mendes Junior, E., Oliveira, B. E. S. de, Rocha, C. F., et al. (2022). New relapse of multiple sclerosis and neuromyelitis optica as a potential adverse event of AstraZeneca AZD1222 vaccination for COVID-19. Multiple Sclerosis and Related Disorders, 57, 1-5. doi:10.1016/j.msard.2021.103321NLM
Fragoso YD, Gomes S, Gonçalves MVM, Mendes Junior E, Oliveira BES de, Rocha CF, Santos GAC dos, Tauil CB, Araujo RV, Peron JPS. New relapse of multiple sclerosis and neuromyelitis optica as a potential adverse event of AstraZeneca AZD1222 vaccination for COVID-19 [Internet]. Multiple Sclerosis and Related Disorders. 2022 ; 57 1-5.[citado 2024 out. 31 ] Available from: https://doi.org/10.1016/j.msard.2021.103321Vancouver
Fragoso YD, Gomes S, Gonçalves MVM, Mendes Junior E, Oliveira BES de, Rocha CF, Santos GAC dos, Tauil CB, Araujo RV, Peron JPS. New relapse of multiple sclerosis and neuromyelitis optica as a potential adverse event of AstraZeneca AZD1222 vaccination for COVID-19 [Internet]. Multiple Sclerosis and Related Disorders. 2022 ; 57 1-5.[citado 2024 out. 31 ] Available from: https://doi.org/10.1016/j.msard.2021.103321